Intracranial atherosclerotic stenosis (ICAS) is an important cause of ischemic stroke and transient ischemic attack. For patients with atherosclerotic stroke, it is recommended to use high-intensity statins, cholesterol absorption inhibitors and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for lipid-lowering treatment. This article reviews the current roles of statins and PCSK9 inhibitors in lowering lipids, reducing ischemic events, reducing the degree of vascular stenosis and the effect on atherosclerotic plaque in patients with symptomatic ICAS.

Objective To analyze the effects of intensive treatment with insulin pump and insulin aspart+insulin glargine 3+1.Methods Fifty patients with type 2 diabetes mellitus(T2DM)in our hospital were randomly divided into insulin aspart+insulin glargine(Asp+Gla)group and insulin pump(IP)group,with 25 cases in each group.Compare the general data,biochemical indicators,serum malondialdehyde(MDA),catalase(CAT),superoxide dismutase(SOD)and adverse reactions between the two groups,and calculate the insulin resistance index(HOMA-IR)and islet β function index(HOMA-β).Results HOMA-β,HDL-C,SOD and CAT in the two groups were higher than those before treatment(P<0.05),while FPG,2 hPG,GA,HOMA-IR,TG,TC,LDL-C and MDA were lower than those before treatment(P<0.05).Compared with Asp+Gla group after treatment,HDL-C,SOD and CAT in IP group increased(P<0.05),while FPG,2 hPG,GA,HOMA-β,HOMA-IR,TG,TC,LDL-C and MDA decreased(P<0.05).Conclusions Intensive treatment with insulin pump can more effectively regulate the level of glucose and lipid metabolism,improve insulin β function and reduce oxidative stress,which is safe and effective.

Ischemic stroke is one of the leading causes of death and long-term disability worldwide. The triglyceride-glucose (TyG) index is a biomarker that reflects insulin resistance and metabolic disorders, and is closely associated with the occurrence, progression, and outcome of ischemic stroke. This article summarizes the predictive role of TyG index in patients with ischemic stroke and discusses its potential applications in evaluating stroke outcome and guiding personalized treatment.